



General AML

## Prof. Arnon Nagler | EBMT 2018 | Prospects of immune checkpoint inhibitors for prevention of SCT relapse in AML

 Cynthia Umukoro  Stephanie Hill | Mar 28, 2018

Prof. Arnon Nagler from [Tel Aviv University](#), Tel Aviv, IL, discusses at [44<sup>th</sup> European Society for Blood and Marrow Transplantation \(EBMT\) Annual Meeting](#) the use of immune checkpoint inhibitors for the prevention of post-transplantation relapse in patients with acute myeloid leukemia. Leukemia cells express PD-L1, which they use to evade the immune system and cause relapse. Using checkpoint inhibitors such as nivolumab, a PD-1 inhibitor, might be a strategy to prevent post-transplant relapse in AML patients.

---

© 2018 Scientific Education Support Ltd. This PDF is provided for personal use only. For wider or commercial use, please seek permission from [secretariat@scientificeducationsupport.com](mailto:secretariat@scientificeducationsupport.com) and attribute the source as: <http://www.amlglobalportal.com/medical-information/prof-arnon-nagler-ebmt18-prospects-of-immune-checkpoint-inhibitors-for-prevention-of-sct-relapse-in-aml>